CagriSema: the combination approach The combination of cagrilintide with semaglutide, branded as CagriSema, represents the cutting edge of metabolic peptide therapy
The "maintained improvements" group (approximately 30-40% of users) reports substantial benefit retention 6-12 months post-discontinuation, typically characterized by users who completed 6+ month treatment courses using adequate concentrations (1-2% GHK-Cu), maintained consistent application patterns, addressed underlying skin damage during treatment allowing structural improvements, optimized complementary skincare including sun protection and moisturization, maintained healthy lifestyle supporting collagen synthesis including adequate protein intake and sleep, and possessed favorable genetics for collagen production and skin aging resistance
[PubMed] [Google Scholar] 25.de Morais SM, Uetrecht JP, Wells PG
Growth-hormone secretagogues including GHRH and its analogs such as CJC-1295, and growth-hormone-releasing peptides (GHRPs) such as Ipamorelin are prohibited at all times under section S2 of the WADA Prohibited List (Peptide Hormones, Growth Factors, Related Substances and Mimetics)
Common Side Effects Flushing & GI effects: Flushing, nausea, cramping or lightheadedness can occur, especially if dosed too high or too fast
Glycine Why it might work: Glycine is a simple amino acid with calming and liver-protective properties
